MARKET

CLLS

CLLS

Cellectis
NASDAQ
2.870
-0.170
-5.59%
After Hours: 2.870 0 0.00% 17:52 12/04 EST
OPEN
3.010
PREV CLOSE
3.040
HIGH
3.020
LOW
2.760
VOLUME
286.37K
TURNOVER
0
52 WEEK HIGH
4.040
52 WEEK LOW
0.9628
MARKET CAP
159.53M
P/E (TTM)
-2.3727
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CLLS last week (1127-1201)?
Weekly Report · 1d ago
Weekly Report: what happened at CLLS last week (1120-1124)?
Weekly Report · 11/27 09:42
Weekly Report: what happened at CLLS last week (1113-1117)?
Weekly Report · 11/20 09:42
Cellectis: Report of foreign issuer
Press release · 11/18 00:00
Cellectis: [Amend]General statement of acquisition of beneficial ownership
Press release · 11/16 17:01
Cellectis: Report of foreign issuer
Press release · 11/15 13:00
Cellectis stock jumps on execution of $140M additional investment with AstraZeneca
Cellectis stock jumps on execution of $140m additional investment with astrazeneca. French biotech firm's shares gained 9% premarket on wednesday. Cellectis will receive an initial equity investment of $245m in 2023 from astra zeneca.
Seeking Alpha · 11/15 10:22
Biggest stock movers today: JD.com, Arcturus Therapeutics and more
Shares of jd.com surged 5% after topping expectations in q3. Arcturus therapeutics shares rose 16% after better-than-expected q3 earnings. Cellectis announced an additional investment from astrazeneca in cllsazn. Stock futures inched higher in the early hours of wednesday.
Seeking Alpha · 11/15 10:06
More
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Webull offers Cellectis SA (ADR) stock information, including NASDAQ: CLLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLLS stock methods without spending real money on the virtual paper trading platform.